Druck Icon

IBt-BEBIG wins large tender for implants in Spain

Berlin, September 3, 2008 - International Brachytherapy s.a. (IBt-BEBIG), a European manufacturer of implants for the treatment of prostate cancer, and consolidated within Eckert & Ziegler, announces that it has won a large tender to supply IsoCord® to the renowned Madrid cancer research center Hospital Universitario Ramón y Cajal.

This contract, for product valued in excess of 0.7 million Euros, will further strengthen the position of the company on the Spanish market as a supplier of radiotherapy products. The contract is the fifth long-term supply contract for implants signed with a Spanish hospital since IBt-BEBIG incorporated its Spanish subsidiary earlier this year.


IsoCord® consists of a selectable number of linked seeds used primarily in the treatment of prostate cancer. The IsoCord® system with its convenient and well shielded strand cassette and dispensing device make for quicker procedures and reduced radiation exposure to personnel in the operating room. Long terms study have shown that permanent brachytherapy seed implants provide disease control at least as good as classical radical prostatectomy and external beam radiotherapy but with fewer side effects for patients. Prostate cancer is the commonest form of cancer in men, with about 135,000 new cases diagnosed in Europe every year.


IBt-BEBIG designs, produces and markets worldwide a complete range of radiotherapy implants used in permanent brachytherapy. The group today includes subsidiaries based in Germany, France, UK, Ireland, Spain, and Italy as well as a large number of distributors spread throughout the world.

The Board of Directors